The devolved Welsh Government plans to expand the use of an artificial intelligence-powered tool used to spot cancer in biopsy samples, after seeing a 13% increase in pros
EXACT Sciences presented ten new pieces of data at the San Antonio Breast Cancer Symposium (SABCS) back in late 2022, highlighting the impact of its precision oncology portfolio on breast c
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed